Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis
European Journal of Immunology · 2026-04 · 56 (4)
DOI: 10.1002/eji.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 29.03.2026. Verfasst von Bishnu Prasad Sinha und 10 weiteren Autor:innen. Beteiligte Einrichtung: IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata, India. Hauptthemen laut MEDLINE: Psoriasis, Insulin Resistance, Interferon Type I. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Department of Science and Technology, India, Department of Biotechnology, India, Indian Council of Medical Research.
Abstract (Originalsprache)
Psoriasis is a cutaneous autoimmune disease with worldwide prevalence. In situ activation of skin‐infiltrating plasmacytoid dendritic cells (pDCs) leading to local induction of type I interferons (IFNs) is a crucial innate initiation event in psoriasis. Psoriatic patients also have notable susceptibility to the development of metabolic syndrome, especially systemic insulin resistance. Interestingly, a crucial role of systemic and metabolic tissue‐restricted induction of type I IFNs is now established in metabolic syndrome. We aimed at exploring whether systemic type I IFN abundance contributes to metabolic derangements in psoriatic patients as well. We developed a preclinical murine model of chronic psoriasis that develops systemic insulin resistance, accompanied by a chronic low‐grade systemic inflammation. Then we showed that systemic ablation of type I IFN signaling, using a monoclonal antibody against type I IFN receptor IFNAR1, can mitigate the metabolic dysregulation in this preclinical model of psoriasis‐associated insulin resistance. Thus, we report a hitherto unknown role of systemic type I IFN abundance in driving systemic insulin resistance and metabolic dysregulations in psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
- University of Florida Diabetes Institute, University of Florida, Gainesville, Florida, USA.
- Department of Biology, Trivedi School of Biosciences, Ashoka University, Sonipat, India.
- Datla Human Immunome Lab, Trivedi School of Biosciences, Ashoka University, Sonipat, India.
Förderung
- Department of Science and Technology, India
- Department of Biotechnology, India
- Indian Council of Medical Research
Zitieren
APA
Sinha, B. P., Bandopadhyay, P., Hoque, M. A., Liu, C. S. C., Mukherjee, S., D'Rozario, R., Roy, S., Jana, R., Pattanayak, S., Sarif, J., & Ganguly, D. (2026). Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis. European Journal of Immunology, 56(4). https://doi.org/10.1002/eji.70160
Vancouver
Sinha BP, Bandopadhyay P, Hoque MA, Liu CSC, Mukherjee S, D'Rozario R, et al. Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis. European Journal of Immunology. 2026;56(4). doi:10.1002/eji.70160
BibTeX
@article{Sinha2026,
author = {Sinha, Bishnu Prasad and Bandopadhyay, Purbita and Hoque, Md Asmaul and Liu, Chinky Shiu Chen and Mukherjee, Suravi and D'Rozario, Ranit and Roy, Shreya and Jana, Rituparna and Pattanayak, Shrestha and Sarif, Jafar and Ganguly, Dipyaman},
title = {Systemic Type I Interferon Blockade Mitigates Insulin Resistance in a Preclinical Model of Psoriasis},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {4},
doi = {10.1002/eji.70160}
}
EUVIMED